中國水務(00855.HK)就湖南直飲水項目訂戰略合作協議
中國水務(00855.HK)公布,公司與懷化水務投資已訂立合作協議,內容有關於湖南省懷化市的直飲水項目的戰略合作。根據協議,公司全資附屬銀龍與懷化水務投資的指定附屬將於湖南省懷化市現有供水系統的基礎上共同投資建設管道直飲水供應系統。該等項目擬分階段進行,目的為於五至十年內將高質量的管道直飲水接入用戶家庭、工作場所、學習及其他生活場所。
集團預期,管道直飲水系統將覆蓋約60萬人口,每日直飲水供應能力約為1,800噸。訂約各方將成立聯合工作小組磋商具體合作條款。預期該等項目將由與懷化水務投資指定的附屬公司組成的合資企業進行。合資企業的建議註冊資本為5,000萬元人民幣,而銀龍將持有60%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.